Don L. Gibbons

The University of Texas MD Anderson Cancer Center

Full Professor(heuristic)

Lung Cancer Treatments and Mutations · Pulmonary and Respiratory Medicine

h-index83

i10-index224

Publications1,201

Citations24,543

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 317

Supplementary Table 2 from ZEB1 Is Regulated by K811 Acetylation to Promote Stability, NuRD Complex Interactions, EMT, and NSCLC Metastasis
2026-06-19
Supplementary Table 5 from ZEB1 Is Regulated by K811 Acetylation to Promote Stability, NuRD Complex Interactions, EMT, and NSCLC Metastasis
2026-06-19
Supplementary Table 3 from ZEB1 Is Regulated by K811 Acetylation to Promote Stability, NuRD Complex Interactions, EMT, and NSCLC Metastasis
2026-06-19
Supplementary Table 6 from ZEB1 Is Regulated by K811 Acetylation to Promote Stability, NuRD Complex Interactions, EMT, and NSCLC Metastasis
2026-06-19
Supplementary Table 1 from ZEB1 Is Regulated by K811 Acetylation to Promote Stability, NuRD Complex Interactions, EMT, and NSCLC Metastasis
2026-06-19
Supplementary Table 4 from ZEB1 Is Regulated by K811 Acetylation to Promote Stability, NuRD Complex Interactions, EMT, and NSCLC Metastasis
2026-06-19
Supplementary Figures 1-8 from ZEB1 Is Regulated by K811 Acetylation to Promote Stability, NuRD Complex Interactions, EMT, and NSCLC Metastasis
2026-06-19
Table S1 from Inflammation Mediated by Gut Microbiome Alterations Promotes Lung Cancer Development and an Immunosuppressed Tumor Microenvironment
2026-06-17
Figure S1 from Inflammation Mediated by Gut Microbiome Alterations Promotes Lung Cancer Development and an Immunosuppressed Tumor Microenvironment
2026-06-17
Supplementary Figure S3 from Mechanisms of Response and Tolerance to Active RAS Inhibition in <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer
2026-06-17
Table S5 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
2026-06-17
Supplementary Figure S1 from Mechanisms of Response and Tolerance to Active RAS Inhibition in <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer
2026-06-17
Supplementary Figure S14 from Mechanisms of Response and Tolerance to Active RAS Inhibition in <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer
2026-06-17
Figure S5 from Inflammation Mediated by Gut Microbiome Alterations Promotes Lung Cancer Development and an Immunosuppressed Tumor Microenvironment
2026-06-17
Figure S3 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
2026-06-17
Supplementary Figure S15 from Mechanisms of Response and Tolerance to Active RAS Inhibition in <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer
2026-06-17
Figure S1 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
2026-06-17
Supplementary Figure S6 from Mechanisms of Response and Tolerance to Active RAS Inhibition in <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer
2026-06-17
Table S1 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
2026-06-17
Table S2 from Inflammation Mediated by Gut Microbiome Alterations Promotes Lung Cancer Development and an Immunosuppressed Tumor Microenvironment
2026-06-17

Open author page on OpenAlex →